-
Signature
-
/s/ Will Solis, Attorney-in-Fact
-
Issuer symbol
-
BBIO
-
Transactions as of
-
10 Mar 2026
-
Net transactions value
-
-$624,312
-
Form type
-
4
-
Filing time
-
12 Mar 2026, 16:15:36 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Valantine Hannah |
Director |
C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO |
/s/ Will Solis, Attorney-in-Fact |
12 Mar 2026 |
0001855608 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BBIO |
Common Stock |
Options Exercise |
|
+8,671 |
+116% |
$27.36* |
16,136 |
10 Mar 2026 |
Direct |
|
| transaction |
BBIO |
Common Stock |
Sale |
$624,312 |
-8,671 |
-54% |
$72.00 |
7,465 |
10 Mar 2026 |
Direct |
F1 |
| holding |
BBIO |
Common Stock |
|
|
|
|
|
398 |
10 Mar 2026 |
By Spouse |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
BBIO |
Stock Option (Right to Buy) |
Options Exercise |
|
-8,671 |
-33% |
$0.000000* |
17,343 |
10 Mar 2026 |
Common Stock |
8,671 |
$27.36 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: